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gene is devalopmentalry eguia~d and it is the major Isaform expressed in 
adult rat heart In pressure load induced h y ~  expression of this 
isoform is down regulated. The mechanism of its negative regulation Is 
virtually unknown, By promoter analysis, we have found that the sequences 
of =-MHC gane encompaasing -600 to +420 10p cloned upstream of a 
ch in~nlco l  acetyl transfemse (CAT) reporter, m sufficient o ddve its 
muscle-specific expression In adult rat heart and in muscle coil line Sol8 
but no ac t~ was observed in non mus~e calls JEG and NIH3T3. Using 
deletion mutant conelnJcts, a strong negative regulatory element (NRE) was 
located 60 109 dew~-,si~6am of the I~nsorip~on start site. Dalai/on of this 
region resulted in 20 told induction of a-MHC/CAT expm~ion in adult hearts 
and in Sol8 cells. This routemen also resulted in expression of ~-MHC/CAT 
constructs in JEG cells that was othenMse inert in this cell line. Qel-shltt 
analysis with NRE sequences howed specific intemc~on of nuclear factors 
Imm ;;zlult head. Sol8 and JEG cags and each of these nuclear extracts 
produced ddferent mobility DNA-protein complexes. The nucisotides required 
within 35 bp NRE region for faster interaction were also found d'dferant in three 
nuclear extracts analyzed. These data may provide in part, the mechanism 
for its tissue specific expression and modulation of expression in the adult 
rat heart (Supported by a grant from Christ Hospital Med Fund). 
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~ Regression of  Postprandial LIpemla After 
SmokMg Cessation 
J~)rg Muntwyler, Hansruedi Schmid 1 Heinz Drexel, Dieter 
J. Vondemchmitt I Josef R. Patsch2 Frasz W. Amann. Division of 
Cardiol~, University Hospital, ZOrich, Switzerland; ~ Institute of Clinical 
Chemistry, University Hospital. ZOrlch, Switzerland; 2 Depa~ent of 
Medicine, Unive~y of Innsbruck, Aus~a 
Several studies found a positive, independent association between postpran- 
dial tipamia and alherescisrosis. Smokers have higher fasting Idglyceride 
0"G) levels, probably c~used by decreased levels of lipopreteln lipase (LPL). 
In the animal model, carbon monoxide and cigarette smoke depresses clear- 
ance of chyiomicron remnants. Therefore, we investigated this Issue in man, 
Methods: Measurement of fasting liplds and postprandial tipamiain 8 healthy 
smokers before and 3 weeks after smoking cassaffon. No other change in 
tifestile was allowed. As a marker for postprandial lipid/;, 50,000 U Vitamin 
A/m 2 BSA was ingested with a standardized fat load. After ultracentrifuge- 
lion, retinyl palndtate (RP) was measured by HPLC in the chyiomicron (CM: 
Sf > 1000) and chylomicren remnant (CMR: Sf < 1000) fra~on. Results: 
Var~t:~m ~a~mllne Smoking ~,% p-Value 
Sn~dng ~t iQn 
AUG TG (mmol~ x 10 h| 35.7 :l: 11.5 27.5 =1: 7A -23% 0.11 
AUIC total RP (p~g/nd x 10 h) 41.2-;- 11.4 29.7 :E 7.1 -28%0.05 
AUCRPCM(pg/mlxl0h) 30.7+9.4 21.44-5.1 -30%0.10 
AUICRPCMR(t~g/mlxl0h) 10.6:1:2.1 2.3.;-2.2 -22%0,03 
AU(I}C: Area under the (incremental) curve 
After smoking cessation, fasting HDL-C and ape A-I increased and tri- 
gylycaddes decreased (p all < 0.05). LPL increased and was s'tgn~ticantty 
(p < 0.01) correlated with the increase of HDL-C. Conclusion: After smok- 
ing cessation, postprandial lipamla decreases; this regression Is particularly 
significant for the fraction containing chylomicron remnants, the potential 
atherogenlc particles in the postprandial I pamla, and might explain a part of 
the increased alheroscleresis risk in smokem. 
~'~'~ Plasma Homocysteine Levels Predict Brachlal 
Artery Vasoroactlvlty In Patients With Coronary 
Artery Disease 
Mark R. Izzo, Marc D. Feklman, Clarence Wu, M, Zubalr Jafar, 
Katherine Jacobs, Warren Divert, Loma Cropcho, John George, Peter 
J. Counlhan. Univemity of Pittsburgh, Pittsburgh, PA 
Plasma hornocystalne has been ehewn In vivoto cause endothelial damage. 
The hyperemic brachisl artery response to ischanlla is a noninvasive test to 
evaluate endothelial function. Patients with CAD have been shown to have 
abnormal endothelial function as measured by hyperemk: brachial artery 
response. We hypothesizedthut h0mcoystalns may contn'bute to endothelial 
dysfonc~on in patients with CAD as assessed by brachlal aden] hyperemic 
response. Methods: Relative plasma homcoystslne levels were measured 
at 0 and 6 houm by methlonlrm loading In patfents beth at basaline and an 
vitamin treatment (136 and fotic acid). Brachisl ertery vesodgatory response 
to 4 minute BP cuff occlusion was measured in patients with angiographlcelly 
documented CAO(n = 51). Results: Relative plasma homocyntelne levels 
and hyperemio brachlal arte~ response significantly correlated (p - 0,005) 
as shown below, 
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Conclusion: Elevated I~rnocys~ino levels are associated with an atten- 
uated brachial artery hyperemio response. Hornowstaine may contfibuto to 
endo~elial dysfunction in patients with CAD. 
~ " ~  Effects of  Con]ugated EMmgens  A lone and 
Combined With Pravastatin for Management of 
woHYOPercholesterolemla In Postmenopausal  
men 
M.H. Oavidson, LM. Testolln, K.C. Maid, S. von Duvillard 1, K.B. Drannan. 
Chicago Center for Clinical Research, Chicago, IlUnois; 1 William Patterson 
Coflege, Wayne, New Jersey 
The aim of the present study was to evaluate and compare the lipid alter- 
ing effects of conjugated ealrogens (CE, 0.625 rag/d), pravastatin (PRAV, 
20 rag/d), and combined CE + PRAV therapy among hyperoheisstorolemio 
postme~ women. After six weeks of following an NCEP Step I dist, 
76 subjects (mean age = 61 years) wore randomly assigned to receive CE, 
PRAV. CE + PRAV. or placebo for 16 w~sks in a parallel fashion. No signifi- 
cant differences in demographic or lipid values were present between groups 
at l~tsei|ne (mean LOL-C = 199 n~/dL). Sixty-seven subjects con~etnd at 
least two post-randomization visits. Mean % change (SO) from baseline in 
lipid parameters are shown in the table (average of four samples taken at 
monthly intervals). 
Variable Placebo CE PRAV CE + PRAV 
TC 2.5 (9.7) 2`3`4 --6.2 (8.1) 1.3`4 -18.5 (7,2) 1,2 -15.8 (10.3) 1,2 
LOL-C 1.0(11.3) 2.3A -13.7(8,1)1.3A -25.0(9.3)t.2 _27.0(1§.2)t,2 
HDL-C -2.9 (7,7) 2'4 25,3 (19.8) 1,3 4.8 (13.9) 2.4 2~.2 (11.~)1.3 
I~IIG 15.1 (38.5) 3 9,8(36.2) 3 ~10-9 {16.7) %2 0.0(16.8) 
LDL/HDL 5.3 (13.2) 2`3`4 -28.6 (11.0) 1"4 -27.7 (10.2) 1,4 -39.7 (17.~) 1,2,3 
1,2,3`4p < 0.05 vs. placebo° C r:, PRAV, CE + PRAV. respectively 
Both CE and PRAV improved the serum lipid profile, and the two combined 
were more effective at reducing the LDL-C/HDL-C ra~o than either treat- 
ment alone. These data support the NCEP's recommendation to consider 
estrogen replacement as an Initkd or adjunct herapy for the management of 
hypemholasterolemta in postmenopausal women. 
~ Impaired Endothel lum-dependent Vasodllator 
t(es .ponse In Petlents With High Llpoproteln(e) 
iL,¢VelS 
Tatsuaki Murakaml, Sumio Mtzuno, Yeshlyuki Aral, Yoshifumi Takehash|, 
Masateru Ohnaka. Fukul CerdiovaScu/ar Center, Fukul, Japan 
Endothelial dysfunction is supposed Io be a major factor that con~toe  
to the atherogenic or thrombngenio processes, and tipoprotein(a):Lp(a) has 
been documented as an independent risk factor for atherosclerosls or my- 
ocanJlal intarotlon. In order to determine whether elevated I.p(a) isvale impair 
endothallum-depaedent vasedllator esponse of coronaP/~ulely, we e,~lu- 
ated changes in coronary blood flow dynamics assessed by quastltalive 
~ .rpnary.artedography and intra¢orenary doppler-tipped guidewlra (Re Wire 
qn patients with (11 ,= 23) high Lp(a) levels (> 33 log/Q), and compared 
them to those in control patients without high L.p(a) levels (71 overall conlrois 
and 23 matched controls in age, gender, and serum total cholesterol level. 
We infused anetylcholine into the study coronary artery, and estimated the 
coronary diameter and the flow velocity. In patients with high Lp(a) levels, 
acetylcholine-leduced maximal Increases In the coronen/diameter and the 
coronary blood flow were smaller than those in the control patients. Maximal 
increases in the coronary diameter were 1.6 4- 2.5% (Mean .4- S.D.%) in the 
patients with high Lp(a) levels, 3,9 ~: 3.2% in the overall control patients, and 
.3.7 .~ ~ In ~..e matched control patients (, < 0.0S; patients with high Lp(a) 
zevels vs ovem. ann matched controls). Maximal Increases in the comnaly 
blood flow were 39.5 :J: 28.4% in patients with high L.p(a) levels. 95.9 4- 81,2% 
JACC Fdorus~ 1996 ABSTRACTS-Poster 413A 
In the overall control patients, 113.20 :b 89.8% In the matched control patients 
(p < 0.01; patients w~h high Lp{e) levels ve overall and matched conVols). 
Maximal Inoreasos In the coronary diameter had nsgative correlations with 
Lp(a) levels (p < 0.05, r - -O.25 and -0.35; ~te  with thgh Lp(a) k~s  ve 
overall and matched controls, respo,~aly). Maximal Increases In the com- 
naly blood flow had also negative collations with Lp(a) levels (p < 0.01, r 
= -0.31 and -0.48, patients with hk]h Lp(a) levels ve overall and matched 
controls, respectively). These results suggested elevated Lp(a) levels impair 
endothallum.dependent vasodilster response, which may conifibute to ac- 
celera~d athemgenlo r ~rombogenls ~ In pa~ents with hlgh Lp(a) 
tevels, 
~ Comparat ive Effect of  Pravaststln and 
S lmvuts t ln  on Platelet.Thrombus Formation In 
Hypercholaslerolemlc Coronary Pal lents 
Lucle Lacoete, Jules Y.T. Lain. Montreal Heart Institute, Monlmal, Quebec, 
Can~ 
High cholesterol (¢hol) is a risk factor for coronary atherosClerOsls and re- 
ducing elevated cholesterol has been shown to prevent coronary morblo~ly 
and moriardy. Hypercholastomlemic pts also have hyperactive platslets and 
an increased tendency to platelet-thmmbus formation at the site of an in- 
jured artedal wall. This pmthombot~e t ndency may favor the development 
of acute Ischemic coronary ovens due to coronanj thrombosis at the site of 
plaque rupture. Whether, reduction of serum cholesterol with the HMG-CoA 
reduclase inhlbitom, pravastatin (Pmva) or slmvastatin (Simva), will intiuenca 
pletslet thrombosis In stable coronary pts taking aspldn, 325 mg/day, was 
assessed before and after 2-3 months of Prava therapy (40 rag/day, n = 16) 
or Simva therapy (20 rag/day, n = 16). Platelet thrombos fonaation (PT) was 
evaluated by exposing porolna aortic media (simulating deep arterial Injury) 
to the pt's flowing venous blood for 3 rain at shear rates of 2546 and 754 
s "1 at 3"FC in a superlusicn chamber ex vive. Serum lipide and quantita- 
tive marphometne PT (izn~'lmm) before and after drug tma~-nsnt are shown 
below: 
Shear ate Basal Prays Basal Simva 
PT: 2546 **-1 2.0±0.4 1.0 4. 0.2 "? ;!.1 4-0A 2.04-0.4 
7548 -1 1.7.~0.4 0.94-0.1"t 1.8~0.4 1.84-0.4 
Chat: Tolal 6.1 4-0.1 4.6 :t: 0.2" 5.5::1:0.3 4.7 ± 0.2" 
(mmol~.) LDL 4.1 4-0.1 2.84-0.1" 4.54-0,3 2.84-0.2* 
• p < 0.05 vs basal, l";p < 0.05 vs SImva 
Thus, both Simva and Prave decreased somm total and LDL cholesterol, 
but pletstet hrombosis was inhibited mare by preva at both the high and low 
shear rates tested. These resu~ suggest that after 2-3 months of therapy, 
HMG-CoA reductase inhibitom may have a differential effect on platelet 
thrombosis which may influence the early clinico-pethotegic evolution of the 
coronary atherosolaro~c process. 
• Pl~:e. nt Cholesterol Absorpt ion in Normal Human 
~ublec'ts by Negative Ion Gas Chromatography 
Mass Spectrometry 
Matthew S. Besnar, William Sfanson, Pat~ Tumbough, Stephen Block, 
Laura Koboyashi, Abigail Schweizar, R ~  E. Oetlund, Jr.. Jewish 
Hospital and Wash~ton University School of Medicine, St. Louis, MO 
Percent cholesterol (CH) absoq~tion was measured in 70 normal subjects on 
their ambient diet by simultaneous adminlslration of 30 mg CH [23,24,25,26, 
2.~3-C5..-GH orally v~ a standard meal and 15 tag [26,26,26,27,2-/, 
-H6-CH IV. Blood was collected on days 0 and 3, CH isolated, and 
darivalized to a pent~uorobenzoyl ester, and the ratio of isotopic tracer ana- 
lyzed by negative ion gas chromatography mass epecVomeW. The resulting 
mass spectra consisted almost solely of intense molecular GH lens pem~it- 
ling detection of 20 final of tracer. Percent CH absoq~icn was 56.8 + 11.5% 
(mean 4- SO, N = 70, age 18 to B2 years, 51 female, 19 male), confkmlng 
heterogeneity of CH absoq)tion In normal humans. CH absoq~don was not 
re.ted tO age, gender, plasma, llp[ds or apepreteln levels including apo-E 
genotype (by PCR). Chronic dietary calories, dtetanj % fat or CH composition. 
or fiber quantitstsd from 7-day food records were not related to CH. CH was 
signlrcangy negatively correlated with plasma insulin (r = -0.250, p = 0.549) 
and plasma ~t ide  (-0.25, p ,, 0.0079). Thus percent CH absorption may 
be regulated by insulin and altered by insulin resistance. The SD between 
tests performed 4-6 weeks apart was 2.8% suggesting stability over time. 
This novel and broadly applicable method may provide a precise technique 
to quanl~ Inten~antiona such as ~et or o'nJgs on CH absor~on in humans. 
~ Immune Responses to HMG-CoA Reductase 
Inhlbltors in Patients With Abnormal  Upid Level 
Minh N. Bul, Mk'haal 1". Caulflald, Paul Kalz, Richard O. Cannon III, Charles 
E, Reckley. Georgetown Univers~ Medical Center, Washington, DC; 
NHLBI, NIH, Bethesda, MD 
Gflnloal trials with HMG-COA reductssa Inhlbitom have reported decrease In 
clinical events out of proportion to small anatomical changes In coronary an- 
glogmm, Previous finding from our lab has shown that HMG-COA reduclasa 
inhlbltere cause a rise in IDG autoantibodies to oxidized LOL(ox-LDi) during 
the first 6 months of therapy. However, the autoantibodles tilers decrease by 
t2 months. We examined the potential Immune response in hypedipldemlc 
patients treated with HMG-COA reductase inhibitom, A nonlsotopta EUSA 
technique was used to measure autoantibodies titem in 11 I~tients with 
hypefllpldemla. LDL, IgG and IgM autoantibodles titem were measured at 
baseline and at 4 d: 1.4 months after tma~nent with HMG-COA mdu,~tese 
fnhlbitom. 
Baseline 4 months 
LOt. (rag/d1) 17~. 4. 37 138 :)= 28" 
Autoantn)odles to ox.LDI. (OD) 
IgG 0.1384- 0.076 0.1544.0.087 
IgM 0.0244-0.019 0.053 d: 0.044" 
• p-value < 0.0S vs. baseline by paired Student t-teal; OD: optfcat density 
Conclusion: 1) A decrease in LDL level was associated with an Inc~eese in 
eutoantibodies tltom to ox-LOL. 2) Early In~'ease in autoantibodles titsrs was 
greater with tgM than IgG. 3) These early immune responses may contribute 
to plaque stabilization. 
